HKD 59.51 consensus target leaves WuXi Biologics stock 22.35 percent below target
Published on 10/15/2026 at 21:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSTarget and valuation guide
- A 25-analyst consensus target stood at HKD 59.51 on October 10, 2026.
- WuXi Biologics carried a price-to-earnings ratio of 34.85 on October 15, 2026.
- WuXi Biologics stock cost EUR 5.51 at Lang & Schwarz on October 15, 2026 at 9:05 p.m. CEST, down 2.21 percent on the Hong Kong Stock Exchange.
- Market capitalization stood at HKD 200.2 billion on October 15, 2026.
A 25-analyst consensus target stood at HKD 59.51 on October 10, 2026, putting it 22.35 percent above WuXi Biologics' HKD 48.64 Hong Kong share price, according to Simply Wall St. At Lang & Schwarz, WuXi Biologics stock was trading at EUR 5.51 on October 15, 2026 at 9:05 p.m. CEST, down 2.21 percent on the Hong Kong Stock Exchange.
Target sits above the share price
The consensus target is above the latest Hong Kong quotation, while the target range runs from HKD 43.21 to HKD 77.78. The spread shows that expectations remain wide even within the published analyst estimates. The HKD 59.51 consensus target is 22.35 percent above HKD 48.64, using the same Hong Kong currency for both figures.
Price position remains below the high
WuXi Biologics' Hong Kong shares stood at HKD 48.64 on October 15, 2026, down HKD 1.10 from the prior close of HKD 49.74. The 52-week range was HKD 28.48 to HKD 58.00, leaving the share price 16.14 percent below the high and 70.76 percent above the low. Trading volume reached 40,225,203 shares against an average of 34,860,993.
The Hong Kong quotation's market capitalization was HKD 200.2 billion on October 15, 2026, while the price-to-earnings ratio was 34.85. The stock's dividend yield was zero in the same quotation data. WuXi Biologics describes its business as an integrated provider of biologics discovery, development and manufacturing services, including drug substance and drug product production, on its WuXi Biologics investor page.
Comparison with peers
What the valuation shows
The company therefore combines a higher price-to-earnings ratio than CSPC Pharmaceutical Group with a lower ratio than BeOne Medicines. Its market value sits between the two peers, while the consensus target remains above the latest Hong Kong share price.
Euro quote after hours
WuXi Biologics was trading at EUR 5.51 at Lang & Schwarz on October 15, 2026 at 9:05 p.m. CEST, down 2.21 percent on the Hong Kong Stock Exchange. In Hong Kong, the stock closed at HKD 48.64 on October 15, 2026, within its HKD 28.48 to HKD 58.00 52-week range. The further course of trading is shown by the continuously updated real-time quote of WuXi Biologics stock.
WuXi Biologics stock data
- Company: WuXi Biologics (Cayman) Inc.
- ISIN: KYG970081173
- Ticker: 2269.HK
- Primary exchange: Hong Kong Stock Exchange
- Price Lang & Schwarz (as of October 15, 2026, 9:05 p.m. CEST): EUR 5.51
- Change on the Hong Kong Stock Exchange: minus 2.21 percent (October 15, 2026)
- Market capitalization: HKD 200.2 billion (as of October 15, 2026)
- 52-week range: HKD 28.48-HKD 58.00 (as of October 15, 2026)
- Sector / Industry: Healthcare / Biotechnology
Market context: Current market reports.
